This Article Free Full Text (Free PDF) Free All Versions of this Article: 0269881105056657v1 20/1/80    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wichniak, A. Articles by Jernajczyk, W. Search for Related Content PubMed PubMed Citation Articles by Wichniak, A. Articles by Jernajczyk, W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Schizophrenia Social Bookmarking                         What's this?

Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment

Third Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland, wichniak{at}ipin.edu.pl

Tomasz Szafraski

Third Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland

Aleksandra Wierzbicka

Department of Clinical Neurophysiology, Institute of Psychiatry and Neurology, Warsaw, Poland

Elbieta Waliniowska

Department of Clinical Neurophysiology, Institute of Psychiatry and Neurology, Warsaw, Poland

Wojciech Jernajczyk

Department of Clinical Neurophysiology, Institute of Psychiatry and Neurology, Warsaw, Poland

Electroencephalogram (EEG) slowing is associated with clozapine side effects, e.g., sedation, and may predict treatment response during clozapine treatment. As olanzapine and clozapine share many pharmacological properties, we investigated whether EEG slowing during olanzapine treatment was related to therapy outcome and sleepiness in patients with schizophrenia.

Participants were age- and gender-matched schizophrenic patients treated with olanzapine (n 54), receiving no pharmacological treatment (n 54), or cotreated with olanzapine and some other psychotropic drug (n 38). Their EEG recordings were assessed visually by the same rater blind to clinical data. The EEG scores were categorized using standardized forms.

Patients with a poor treatment response did not differ significantly from those with a good response to treatment either in EEG patterns or in frequency of sleepiness. Olanzapine treatment was associated with increased rates of slow (70.4% vs. 22.3%) and sharp waves (22.2% vs. 7.4%), as well as of paroxysmal slow wave discharges (14.8% vs. 1.9%), but did not induce spike- or sharp-slow-wave complexes. Cotreatment with another antipsychotic further increased EEG abnormalities, whereas benzodiazepine administration diminished the olanzapine-induced EEG changes.

The results show that olanzapine inducing both slow and sharp waves, as well as paroxysmal discharges, has a strong impact on EEG. However, as no spike- or sharp-slow-wave complexes were observed, the risk of epileptic seizure during olanzapine treatment can be regarded as low, as long as olanzapine is not combined with some other antipsychotic.

Key Words: EEG • pharmaco-EEG • visual analysis • treatment outcome • sleepiness • antipsychotic treatment

This version was published on January 1, 2006

Journal of Psychopharmacology, Vol. 20, No. 1, 80-85 (2006)
DOI: 10.1177/0269881105056657


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?